Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Enrolling by invitation Observational

Adenomyosis Clinical, Imaging and Histopathology

NCT07237932 · tracked via the Priya Life Science Egypt tracker
Phase
Observational
Started
2025-04-30
Last updated
2026-07-08

Condition(s) studied

Adenomyosis

Study summary

The goal of this clinical trial is to identify and compare the results of imaging studies and evaluating adenomyosis features and post hysterectomy results and their clinical relievants as well as to describe classification for adenomyosis based on one or a combination of clinical, imaging and histopathological features.

Main questions it aim to answer:

What's the relation between clinical symptoms ,maging and histopathological classification of adenomyosis? Research will identify relationships between clinical symptoms, imaging and histopathological classification of adenomyosis Participants will undergo transvaginal ultrasound, non contrast pelvic MRI, hysterectomy then histopathological examination for their uterus

Eligibility

Sex
FEMALE
Min age
35 Years
Max age
55 Years
Healthy volunteers
No
Inclusion Criteria: Age from 35 to 55 years old female No previous hormonal treatment for uterine adenomyosis within three months Women with heavy menstrual bleeding and dysmenorrhoea Women who completed their families Patient failed medical treatment and hysterectomy is the only remaining line for treatment - Exclusion Criteria: Patients not candidate for hysterectomy Positive pregnancy test Patients with contraindications for MRI such as patients with pacemakers, claustrophobia,or other implanted electronic devices Inadequate image quality due to motion artifact \-

Primary outcome measure(s)

  • Classifications of adenomyosis — 12 months
    Class of adenomyosis according to imaging, histopathology and clinical outcomes

Trial sites (1)

FacilityCityRegionStatus
Kafr elsheikh university Kafr ash Shaykh Egypt

Other trials for the same condition

Ttt of Adenomyosis Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07237932 on ClinicalTrials.gov ↗ ← All trials in Egypt